Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

March 31, 2022

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 or 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from  _____  to  _____

 

Commission File Number: 1-5005

 

INTRICON CORPORATION

(Exact name of registrant as specified in its charter)

 

Pennsylvania

 

23-1069060

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer Identification No.)

incorporation or organization)

   

1260 Red Fox Road

  

Arden Hills, Minnesota

 

55112

(Address of principal executive offices)

 

(Zip Code)

 

(651) 636-9770

(Registrant’s telephone number, including area code)

N/A


(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

(651) 636-9770

Trading Symbol

Name of each exchange on which registered

(Registrant’s telephone number, including area code)

Common stock, par value $1.00 per share

N/A

IIN

Nasdaq Global Market

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

☒  Yes  ☐  No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  ☒  Yes  ☐  No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”,filer,” “accelerated filer”filer,” “smaller reporting company,” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer

Non-accelerated filer

Smaller reporting company ☒

  
Non-accelerated filer  ☐  (Do not check if a smaller reporting company)Smaller reporting

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act).

☐  Yes  ☒  No

 

The number of outstanding shares of the registrant’s common stock, $1.00 par value, on October 31, 2017April 30, 2022 was 6,869,013.9,302,316.

 

INTRICON CORPORATION

 

I N D E X

  

Page

Numbers

PART I: FINANCIAL INFORMATION

Item 1.

Condensed Consolidated Financial Statements (Unaudited)

   
 

Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2022 and 2021

Page
Numbers

3

PART I: FINANCIAL INFORMATION
   
 

Item 1.Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three Months Ended March 31, 2022 and 2021

Financial Statements4

   
 

Condensed Consolidated Condensed Balance Sheets as of September 30, 2017 (Unaudited)March 31, 2022 and December 31, 20162021

3

5

   
 

Condensed Consolidated Condensed Statements of Operations (Unaudited)Cash Flows for the Three and Nine Months Ended September 30, 2017March 31, 2022 and 20162021

4

6

   
 

Condensed Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited)Equity for the Three and Nine Months Ended September 30, 2017March 31, 2022 and 20162021

5

7

   
 

Notes to Condensed Consolidated Financial Statements

Consolidated Condensed Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2017 and 20168

6

   

Notes to Consolidated Condensed Financial Statements (Unaudited)

7-15
Item 2.

Management’sManagement's Discussion and Analysis of Financial Condition and Results of Operations

16-25

19

   

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

26

   

Item 4.

Controls and Procedures

27

26

   

PART II: OTHER INFORMATION

27

   

Item 1.

Legal Proceedings

28

27

   

Item 1A.

Risk Factors

28

27

   

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

28

27

   

Item 3.

Defaults Upon Senior Securities

28

27

   

Item 4.

Mine Safety Disclosures

28

27

   

Item 5.

Other Information

28

27

   

Item 6.

Exhibits

29

28

   

Signatures

 30

29

Exhibit Index31

 

 

PART I: FINANCIAL INFORMATION

 

ITEM 1.Financial Statements

 

INTRICON CORPORATION

Condensed Consolidated Condensed Balance SheetsStatements of Operations

(In Thousands,, Except Per Share Amounts)Amounts)

       
  September 30,  December 31, 
  2017  2016 
  (Unaudited)    
Current assets:        
Cash $332  $667 
Restricted cash  649   595 
Accounts receivable, less allowance for doubtful accounts of $235 at September 30, 2017 and $170 at December 31, 2016  6,853   7,289 
Inventories  14,899   12,343 
Other current assets  1,105   957 
Current assets of discontinued operations     123 
Total current assets  23,838   21,974 
         
Machinery and equipment  40,700   40,152 
Less:  Accumulated depreciation  34,412   33,546 
Net machinery and equipment  6,288   6,606 
         
Goodwill  10,555   10,555 
Intangible assets, net  2,779   2,920 
Investment in partnerships  1,468   146 
Other assets, net  914   1,557 
Total assets (a) $45,842  $43,758 
         
Current liabilities:        
Current maturities of long-term debt $2,411  $2,346 
Accounts payable  8,410   6,722 
Accrued salaries, wages and commissions  2,831   2,413 
Other accrued liabilities  2,830   1,914 
Liabilities of discontinued operations     123 
Total current liabilities  16,482   13,518 
         
Long-term debt, less current maturities  7,014   9,284 
Other postretirement benefit obligations  468   501 
Accrued pension liabilities  754   737 
Other long-term liabilities  685   707 
Total liabilities (a)  25,403   24,747 
Commitments and contingencies (note 11)        
Shareholders’ equity:        
Common stock, $1.00 par value per share; 20,000 shares authorized; 6,860 and 6,820 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively  6,860   6,820 
Additional paid-in capital  22,140   21,383 
Accumulated deficit  (7,349)  (8,633)
Accumulated other comprehensive loss  (740)  (1,014)
Total shareholders’ equity  20,911   18,556 
Non-controlling interest  (472)  455 
Total equity  20,439   19,011 
Total liabilities and equity $45,842  $43,758 
  

Three Months Ended

 

(unaudited)

 

March 31,

  

March 31,

 
  

2022

  

2021

 
         

Revenue, net

 $33,060  $31,768 

Cost of goods sold

  24,188   23,558 

Gross profit

  8,872   8,210 
         

Operating expenses:

        

Sales and marketing

  2,318   1,982 

General and administrative

  4,310   4,052 

Research and development

  1,587   1,293 

Merger-related costs

  1,032   0 

Other operating expenses

  54   35 

Total operating expenses

  9,301   7,362 

Operating (loss) income

  (429)  848 
         

Interest expense, net

  (1)  (9)

Other expense, net

  (152)  (77)

(Loss) income before income taxes

  (582)  762 

Income tax expense

  15   90 

Net (loss) income

  (597)  672 

Less: Income (loss) allocated to non-controlling interest

  60   (42)

Net (loss) income attributable to Intricon shareholders

 $(657) $714 
         

(Loss) income per share attributable to Intricon shareholders:

        

Basic

 $(0.07) $0.08 

Diluted

 $(0.07) $0.07 
         

Average shares outstanding:

        

Basic

  9,256   8,994 

Diluted

  9,256   9,607 

 

(a) Assets of Hearing Help Express (HHE), a consolidated variable interest entity, that can only be used to settle obligations of HHE were $6,408 at September 30, 2017 and $5,159 at December 31, 2016, respectively. Liabilities of HHE, for which creditors do not have recourse to the general credit of IntriCon, were $6,167 at September 30, 2017 and $3,833 at December 31, 2016, respectively.

(See accompanying notes to the condensed consolidated condensed financial statements)

 

 

INTRICON CORPORATION

Condensed Consolidated Condensed Statements of OperationsComprehensive Income (Loss)

 (In

(In Thousands)

  

Three Months Ended

 

(unaudited)

 

March 31,

  

March 31,

 
  

2022

  

2021

 

Net (loss) income

 $(597) $714 

Unrealized foreign currency translation adjustment

  (7)  25 

Realized pension and postretirement obligations

  11   12 

Other

  26   115 

Comprehensive (loss) income

 $(567) $866 

(See accompanying notes to the condensed consolidated financial statements)

INTRICON CORPORATION

Condensed Consolidated Balance Sheets

(In Thousands, Except Per Share Amounts)

             
  Three Months Ended  Nine Months Ended 
  September 30,  September 30,  September 30,  September 30, 
  2017  2016  2017  2016 
  (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) 
                
Sales, net $24,034  $15,570  $66,083  $50,262 
Cost of sales  16,469   12,028   46,261   37,789 
Gross profit  7,565   3,542   19,822   12,473 
                
Operating expenses:                
Sales and marketing  2,342   1,041   6,857   3,357 
General and administrative  2,698   2,221   7,961   6,570 
Research and development  1,047   1,076   3,312   3,562 
Restructuring charges           132 
Total operating expenses  6,087   4,338   18,130   13,621 
Operating income (loss)  1,478   (796)  1,692   (1,148)
                 
Interest expense  (177)  (135)  (548)  (387)
Other expense  (337)  (181)  (328)  (472)
Income (loss) from continuing operations before income taxes and discontinued operations  964   (1,112)  816   (2,007)
Income tax expense  47   33   165   119 
Income (loss) from continuing operations before discontinued operations  917   (1,145)  651   (2,126)
Loss on sale of discontinued operations (Note 3)        (164)   
Loss from discontinued operations (Note 3)     (194)  (128)  (759)
Net income (loss)  917   (1,339)  359   (2,885)
Less: Loss allocated to non-controlling interest  (186)  (35)  (925)  (106)
Net income (loss) attributable to IntriCon shareholders $1,103  $(1,304) $1,284  $(2,779)
                 
Basic income (loss) per share attributable to IntriCon shareholders:                
Continuing operations $0.16  $(0.16) $0.23  $(0.32)
Discontinued operations     (0.03)  (0.04)  (0.12)
Net income (loss) per share: $0.16  $(0.19) $0.19  $(0.44)
                 
Diluted income (loss) per share attributable to IntriCon shareholders:                
Continuing operations $0.15  $(0.16) $0.22  $(0.32)
Discontinued operations     (0.03)  (0.04)  (0.12)
Net income (loss) per share: $0.15  $(0.19) $0.18  $(0.44)
                 
Average shares outstanding:                
Basic  6,853   6,796   6,836   6,287 
Diluted  7,251   6,796   7,179   6,287 

 

(unaudited)

 

March 31,

  

December 31,

 
  

2022

  

2021

 

Current assets:

        

Cash and cash equivalents

 $5,311  $5,584 

Restricted cash

  638   645 

Short-term investment securities

  15,457   19,420 

Accounts receivable, less provision for doubtful accounts of $65 at March 31, 2022 and $69 at December 31, 2021

  11,089   8,257 

Inventories

  28,438   24,456 

Contract assets

  12,589   11,455 

Other current assets

  3,094   4,564 

Total current assets

  76,616   74,381 
         

Property, plant and equipment

  49,779   48,208 

Less: Accumulated depreciation

  34,940   34,371 

Net property, plant and equipment

  14,839   13,837 
         

Goodwill

  13,873   13,873 

Intangible assets, net

  8,595   8,999 

Operating lease right-of-use assets, net

  6,274   5,138 

Investment in partnerships

  596   473 

Long-term investment securities

  4,551   4,558 

Other assets, net

  1,167   1,200 

Total assets

 $126,511  $122,459 
         

Current liabilities:

        

Current financing leases

 $1  $4 

Current operating leases

  1,928   1,807 

Accounts payable

  13,323   9,398 

Accrued salaries, wages and commissions

  4,486   5,185 

Other accrued liabilities

  4,209   3,818 

Total current liabilities

  23,947   20,212 
         

Noncurrent operating leases

  4,426   3,431 

Pension and postretirement benefit obligations

  1,049   1,093 

Deferred tax liabilities, net

  873   873 

Other long-term liabilities

  2,447   3,100 

Total liabilities

  32,742   28,709 
         

Commitments and contingencies (Note 11)

          
         

Shareholders’ equity:

        

Common stock, $1.00 par value per share; 20,000 shares authorized; 9,295 and 9,179 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively

  9,295   9,179 

Additional paid-in capital

  92,255   91,785 

Accumulated deficit

  (7,573)  (6,916)

Accumulated other comprehensive loss

  (363)  (393)

Total shareholders' equity

  93,614   93,655 

Non-controlling interest

  155   95 

Total equity

  93,769   93,750 

Total liabilities and equity

 $126,511  $122,459 

(See accompanying notes to the condensed consolidated condensed financial statements)

INTRICON CORPORATION

Consolidated

Condensed Statements of Comprehensive Income (Loss)

 (In Thousands)
             
  Three Months Ended  Nine Months Ended 
  September 30,  September 30,  September 30,  September 30, 
  2017  2016  2017  2016 
  (Unaudited)  (Unaudited)  (Unaudited)  (Unaudited) 
Net income (loss) $917  $(1,339) $359  $(2,885)
Interest rate swap, net of taxes of $0  3   26   18   (15)
Pension and postretirement obligations, net of taxes of $0  5   5   15   15 
Foreign currency translation adjustment, net of taxes of $0  116   (33)  241   (158)
Comprehensive income (loss) $1,041  $(1,341) $633  $(3,043)

(See accompanying notes to the consolidated condensed financial statements)


INTRICON CORPORATION
Consolidated Condensed Statements of Cash Flows

 (In

(In Thousands)

 

 Nine Months Ended  

Three Months Ended

 
 September 30, September 30, 
 2017 2016 

(unaudited)

 

March 31,

 

March 31,

 
 (Unaudited) (Unaudited)  

2022

  

2021

 
Cash flows from operating activities:         
Net income (loss) $359  $(2,885)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:        

Net (loss) income

 $(597) $672 

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

 
Depreciation and amortization  1,659   1,543  1,460  1,440 

Equity in loss of partnerships

 53  60 
Stock-based compensation  634   506  481  453 
Gain on disposition of property     (55)
Loss on sale of discontinued operations  164    

Change in fair value of contingent consideration

 38  35 
Change in allowance for doubtful accounts  65   (68) (4) (58)
Equity in loss of partnerships  281   175 

Loss on disposal of assets

 10  0 
Changes in operating assets and liabilities:         
Accounts receivable  249   2,346  (2,816) 726 
Inventories  (2,615)  1,189  (3,976) (821)

Contract assets

 (1,134) 320 
Other assets  (658)  (527) 1,489  (410)
Accounts payable  1,712   (1,856) 4,041  3,491 
Accrued expenses  1,228   (954) (631) 206 
Other liabilities  62   12   (72)  (249)
Net cash provided by (used in) operating activities  3,140   (574)

Net cash (used in) provided by operating activities

 (1,658) 5,865 
         
Cash flows from investing activities:         
Purchases of property, plant and equipment  (984)  (1,557) (2,001) (851)
Investment in Soundperience and Other  (730)  (164)
Net cash used in investing activities  (1,714)  (1,721)

Purchase of investment securities

 0  (5,412)

Purchases of intangible assets

 (124) 0 

Proceeds from maturities of investment securities

 3,940  3,752 

Investment in partnerships

  (188)  0 

Net cash provided by (used in) investing activities

 1,627  (2,511)
         
Cash flows from financing activities:         
Proceeds from long-term debt  10,906   14,923 
Repayments of long-term debt  (13,110)  (15,921)
Proceeds from equity offering, net of offering costs     3,678 
Proceeds from employee stock purchases and exercise of stock options  164   83 
Change in restricted cash  (85)  (31)
Net cash provided by (used in) financing activities  (2,125)  2,732 

Payment of financing leases

 0  (11)

Payments on liabilities for acquisition of intangible assets

 (416) (53)

Exercise of stock options and employee stock purchase plan shares

 331  60 

Withholding of common stock upon vesting of restricted stock units

 (226) (241)

Net cash used in financing activities

 (311) (245)
         
Effect of exchange rate changes on cash  364   (202)  62   22 
         
Net increase (decrease) in cash  (335)  235 
Cash, beginning of period  667   369 

Net (decrease) increase in cash

 (280) 3,131 

Cash, cash equivalents and restricted cash, beginning of period

  6,229   9,280 
         
Cash, end of period $332  $604 

Cash, cash equivalents and restricted cash, end of period

 $5,949 $12,411 
 
 

Non-cash investing and financing:

 

Acquisition of property, plant and equipment in accounts payable

 $130  $122 

 

(See accompanying notes to the condensed consolidated financial statements)

 (See accompanying notes to the consolidated condensed financial statements)

INTRICON CORPORATION

Condensed Consolidated Statements of Equity

(In Thousands)

  

Shareholders' Equity, Three Months Ended March 31, 2022 (unaudited)

 
  Common Stock Number of Shares  Common Stock Amount  Additional Paid-in Capital  Accumulated Deficit  Accumulated Other Comprehensive Loss  

Non-Controlling Interest

  Total Equity 

Balances December 31, 2021

  9,179  $9,179  $91,785  $(6,916) $(393) $95  $93,750 

Exercise of stock options, net

  74   74   201   0   0   0   275 

Withholding of common stock upon vesting of restricted stock units

  40   40   (266)  0   0   0   (226)

Shares issued under the employee stock purchase plan

  2   2   54   0   0   0   56 

Stock-based compensation

  -   0   481   0   0   0   481 

Net (loss) income

  -   0   0   (657)  0   60   (597)

Comprehensive Income

  -   0   0   0   30   0   30 

Balances March 31, 2022

  9,295  $9,295  $92,255  $(7,573) $(363) $155  $93,769 

  

Shareholders' Equity, Three Months Ended March 31, 2021 (unaudited)

 
  Common Stock Number of Shares  Common Stock Amount  Additional Paid-in Capital  Accumulated Deficit  Accumulated Other Comprehensive Loss  

Non-Controlling Interest

  Total Equity 

Balances December 31, 2020

  8,951  $8,951  $89,702  $(6,810) $(679) $35  $91,199 

Exercise of stock options, net

  22   22   (15)  0   0   0   7 

Withholding of common stock upon vesting of restricted stock units

  24   24   (265)  0   0   0   (241)

Shares issued under the employee stock purchase plan

  2   2   51   0   0   0   53 

Stock-based compensation

  -   0   453   0   0   0   453 

Net income (loss)

  -   0   0   714   0   (42)  672 

Other

  -   0   0   0   152   (50)  102 

Balances March 31, 2021

  8,999  $8,999  $89,926  $(6,096) $(527) $(57) $92,245 

(See accompanying notes to the condensed consolidated financial statements)

 

INTRICON

INTRI

CON CORPORATION

 

Notes to Condensed Consolidated Condensed Financial Statements (Unaudited) (In Thousands, Except Per Share Data)Da

ta)

 

1.

General

Managements Statement

 

InIntricon Corporation (together with its subsidiaries referred herein as the “Company”, or “Intricon”, “we”, “us” or “our”) is an international company and joint development manufacturer (“JDM”) of micromedical components, sub-assemblies and final devices. The Company serves as a JDM partner to leading medical device original equipment manufacturers (“OEMs”) by designing, developing, engineering, manufacturing, packaging and distributing micromedical products for high growth medical markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. Our mission is to improve, extend and save lives by advancing innovative micromedical technologies through joint development and manufacturing partnerships with industry leading medical device companies.

Basis of Presentation

The interim condensed consolidated financial statements of the Company presented herein have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, the accompanying consolidated condensed financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly IntriCon Corporation’s (“IntriCon” or the “Company”) consolidated financial position as of September 30, 2017 and December 31, 2016, the consolidated results of its operations for the three and nine months ended September 30, 2017 and 2016 and for the cash flows for the nine months ended September 30, 2017 and 2016. Results of operations for the interim periods are not necessarily indicativea fair presentation of the results of operations expected for the full year or any other interim period.

In December 2016, the Company’s board of directors approved plans to discontinue its cardiac diagnostic monitoring business. The Company sold the cardiac diagnostic monitoring business on February 17, 2017 to Datrix, LLC. For all periods presented, the Company classified this business as discontinued operations, and, accordingly, has reclassified historical financial data presented herein. See Note 3.presented.

 

The interim condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.

 

On January 19, 2017,During the three months ended March 31, 2022, the Company announced that it had exercised its option to acquire the remaining 80 percent stake in HHE. The transactionoperated and managed our business under one segment. This is expected to closeconsistent with disclosures in the fourth quarter of 2017. The results of HHE were consolidated intoCompany's Annual Report on Form 10-K for the Company’syear ended December 31, 2021

Certain information and footnote disclosures normally included in financial statements beginning Octoberprepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2016. The Company allocates income and losses to2021, included in the noncontrolling interest basedCompany's Annual Report on current ownership percentage, however, as partForm 10-K. 

Use of the closing, IntriCon will likely absorb a portion of the losses previously allocated to the majority owner. The amount of losses previously allocated to the majority owner that we may have to absorb could range $500,000 and $700,000. Losses incurred by HHE to date include non-cash amortization, acquisition related costs and operating results, all of which are related to prior periods and have no future cash impactEstimates

 

The Company notesmakes estimates and assumptions relating to the reporting of assets and liabilities, the recording of reported amounts of revenues and expenses and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements. Actual results could differ from those estimates. Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of goodwill and intangible assets, including the operating and macroeconomic factors that HHE’s pro formamay affect them. The Company uses historical financial results were not included for 2016 as the company wasinformation, internal plans and projections and industry information in bankruptcy for the majority of 2016 and asmaking such was not reflective of the normal operations of HHE.estimates.

 

In April 2017, the Company entered into an agreement to acquire a 49% stake in Soundperience for 1,200 Euros. As

Summary of September 30, 2017, the Company holds a 16% stake in Soundperience, which will increase to 49% upon the completion of certain milestones and payment of the purchase price for that equity. As of September 30, 2017, the Company has an equity investment and advance in Soundperience of $1,255. Soundperience has designed self-fitting hearing aid technology. The Company’s self-fitting hearing aid technology is being used in the German market today, most notably through our Signison joint venture with the owner of Soundperience. Both Soundperience and Signison will be accounted for in the Company’s financial statements using the equity method.Significant Accounting Policies

 

The Company has evaluated subsequent events occurring after the date of the consolidated financial statements for events requiring recording or disclosure in the consolidated financial statements.

2.New Accounting Pronouncements

In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Retirement Benefits – Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost, guidance that requires entities to present the service cost component of net periodic pension cost and net periodic postretirement benefit cost in the income statement line items where they report compensation cost. Entities will present all other components of net benefit cost outside operating income, if this subtotal is presented. The rules related to the timing of when costs are recognized or how they are measured have not changed. This amendment only impacts where those costs are reflected within the income statement. In addition, only the service cost component will be eligible for capitalization in inventory and other assets. This guidance becomes effective January 1, 2018. Early adoption is permitted. The Company does not anticipate that the adoption of this new standard will have a material impact on its consolidated financial statements.


In January 2017, the FASB issued ASU No. 2017-04 “Intangibles — Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” This new standard simplifies the accounting for goodwill impairments by eliminating step 2 from the goodwill impairment test. The amendments in this update are effective for annual impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for goodwill impairment tests performed on or after January 1, 2017. The Company does not anticipate that the adoption of this new standard will have a material impact on its consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force (the “Task Force”). The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. This update is effective for years beginning after December 31, 2018. The Company has restricted cash balances and anticipates that the adoption of this new standard will change the cash amounts and financing activities on its statement of cash flows on its consolidated financial statements.

In February 2016, the FASB issued its final standard on accounting for leases. This standard, issued as ASU 2016-02, requires that an entity that is a lessee recognize lease assets and lease liabilities on the balance sheet for all leases and disclose key information about leasing arrangements. This update is effective for financial statement periods beginning after December 15, 2018, with earlier application permitted. The Company has not yet determined the impact of this pronouncement on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued new accounting guidance related to revenue recognition, ASC 606. This new standard will replace all current U.S. GAAP guidance on this topic and eliminate all industry-specific guidance. The new revenue recognition standard provides a unified model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration for which the entity expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company beginning January 1, 2018 and can be applied either retrospectively to each period presented or as a cumulative-effect adjustment as of the date of adoption. The Company has established a timeline related to the implementation of the standard and believes the timeline is sufficient to implement the new standard. We are currently assessing the impact on the Company’s consolidated financial statements.

The FASB has issued ASU 2016-10 and ASU 2016-12, which are also related to the revenue recognition standard ASC 606. The Company will adopt the new provisions of this accounting standard at the beginning of fiscal year 2018. The Company is currently evaluating the effect that this guidance will have on its consolidated financial statements.

3.Discontinued Operations

The following table shows the discontinued cardiac diagnostic monitoring business balance sheet as of December 31, 2016:

  December 31, 2016 
Accounts receivable, net $123 
Current assets of discontinued operations $123 
     
Accounts payable  22 
Accrued compensation and other liabilities  101 
Current liabilities of discontinued operations $123 

The following table shows the results of the cardiac diagnostic monitoring discontinued operations:

  Three Months Ended  Nine Months Ended 
  September 30, 2017  September 30, 2016  September 30, 2017  September 30, 2016 
Sales, net $  $445  $140  $987 
Operating costs and expenses     (639)  (268)  (1,746)
Net loss from discontinued operations     (194)  (128)  (759)

The Company sold the cardiac diagnostic monitoring business on February 17, 2017 to Datrix, LLC for a future revenue earn-out that was valued by the Company at $0. The Company recorded a loss on the sale of $164. The net loss was computed as follows:

Accounts receivable, net $179 
Accrued liabilities  (15)
Net assets sold  164 
Fair value of consideration received   
Loss on sale of discontinued operations, net of income taxes $164 

4.Segment Reporting

The Company currently operates in two reportable segments: body-worn devices and hearing health direct-to-consumer. The nature of distribution and services has been deemed separately identifiable. Therefore, segment reporting has been applied.

Income (loss) from operations is total net revenues less cost of sales and operating expenses. Identifiable assets by industry segment include assets directly identifiable with those operations. The accounting policies applied to determine segment information are the same as those described in the summary of significant accounting policies describedare detailed in Note 1 to the financial statements contained in“Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K10-K for the year ended December 31, 2016.2021. The Company evaluatesfollows these policies in preparation of the performancecondensed consolidated financial statements.

8

2.

Pending Merger with Altaris Capital Partners LLC

On February 27, 2022, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") by and among the Company, IIN Holding Company LLC, a Delaware limited liability company ("Parent"), and IC Merger Sub Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Merger Sub"). Parent and Merger Sub are owned by funds affiliated with Altaris Capital Partners, LLC. The Merger Agreement provides, subject to its terms and conditions, for the acquisition of the Company by Parent through the merger of Merger Sub with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the "Merger").

As a result of the Merger, each share of common stock of the Company ("Common Stock") issued and outstanding immediately prior to the effective time of the Merger (the “Effective Time”) (other than Rollover Shares (as defined below) or shares of Common Stock (a) held in treasury of the Company, (b) owned by any subsidiary of the Company, or owned by Parent, Merger Sub or any other subsidiary of Parent or (c) held by a holder who is entitled to, and who has perfected, appraisal rights for such shares under Pennsylvania law) automatically will be converted into the right to receive cash in an amount of $24.25 per share, without interest, subject to any required withholding of taxes.

As permitted by the Merger Agreement, Intricon and certain members of Intricon’s management, or “Rollover Shareholders”, entered into a rollover agreement with IIN Holdings LLC, an affiliate of Parent (“IIN Holdings”), providing for the contribution, immediately prior to the effective time of the Merger, of an aggregate of 127,836 shares of Intricon common stock held by the Rollover Shareholders to IIN Holdings, in exchange for equity interests of IIN Holdings.

The completion of the Merger is subject to customary closing conditions, including: (i) the approval of the Merger Agreement by the Company’s shareholders; (ii) the expiration or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the approval of the Merger under the antitrust laws of other jurisdictions, as applicable; (iii) the absence of any laws or court orders making the Merger illegal or otherwise prohibiting the Merger; and (iv) other customary closing conditions, including the accuracy of the representations and warranties of each segmentparty (subject to certain materiality exceptions) and material compliance by each party with its covenants under the Merger Agreement. The parties expect the transaction to close in the second quarter of 2022, subject to the satisfaction or waiver of the closing conditions.

In connection with the negotiation and execution of the Merger Agreement, the Company has incurred legal, consulting and accounting fees of $1,032 through the quarter ended March 31, 2022.

A special meeting of shareholders of the Company will be held at 8:00 a.m. Central Daylight Time on May 24, 2022, to approve and adopt the Merger Agreement and approve the Merger, among other matters.

9

3.

New Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses Topic 326, which requires certain financial assets to be measured at amortized cost net of an allowance for estimated credit losses, such that the net receivable represents the present value of expected cash collection. In addition, this standard update requires that certain financial assets be measured at amortized cost reflecting an allowance for estimated credit losses expected to occur over the life of the assets. The estimate of credit losses must be based on incomeall relevant information including historical information, current conditions, and lossreasonable and supportable forecasts that affect the collectability of the amounts. Topic 326 is effective for interim and annual periods beginning January 1, 2022 for smaller reporting companies. This standard update did not have a material impact on our financial position, results of operations and cash flows.

4.

Revenue Recognition

Revenue is measured based on consideration specified in the contract with a customer. Revenue from continuing operations before income taxes. all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. For contractual arrangements in which an enforceable right to payment exists, control of these units is deemed to transfer to the customer over time during the manufacturing process. Consequently, the transaction price is recognized as revenue over time. The transaction price for contractual arrangements without an enforceable right to payment including a reasonable margin is recognized as revenue at a point in time. 

The Company’s revenue recognition policy is further detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

During the 2021second quarter, the Company reclassified first quarter revenue of $682 from certain customers in Legacy OEM to Value Based ITEC for the three months ended March 31, 2021. The following tables set forth, for the periods indicated, timing of revenue recognition by market:

Timing of revenue recognition for the three months ended March 31, 2022:

  Products and services transferred at point in time  Products and services transferred over time  

Total

 

Diabetes

 $0  $20,323  $20,323 

Interventional Catheters

  3,271   0   3,271 

Other Medical

  2,363   1,336   3,699 

Value Based DTEC

  685   0   685 

Value Based ITEC

  1,144   0   1,144 

Legacy OEM

  2,726   0   2,726 

Professional Audio Communications

  1,212   0   1,212 

Total Revenue, net

 $11,401  $21,659  $33,060 

Timing of revenue recognition for the three months ended March 31, 2021:

  

Products and services transferred at point in time

  

Products and services transferred over time

  

Total

 

Diabetes

 $0  $18,364  $18,364 

Interventional Catheters

  3,802   0   3,802 

Other Medical

  1,590   1,368   2,958 

Value Based DTEC

  937   0   937 

Value Based ITEC

  1,985   0   1,985 

Legacy OEM

  2,737   0   2,737 

Professional Audio Communications

  985   0   985 

Total Revenue, net

 $12,036  $19,732  $31,768 

10

Net revenue by geography is allocated based on shipment and set forth below:

  

Three Months Ended

 

Net Revenue by Geography

 

March 31, 2022

  

March 31, 2021

 

United States

 $24,021  $23,701 

Europe

  1,963   1,264 

Asia

  2,042   3,468 

All other countries

  5,034   3,335 

Consolidated

 $33,060  $31,768 

Geographic net revenue is allocated based on the shipment location of the Company’s direct OEM customer. These customers then distribute products globally. 

    For the three months ended March 31, 2022, and 2021, one customer accounted for 68% of the Company’s consolidated net revenue.

Two customers combined accounted for 56% and 44% of the Company’s consolidated accounts receivable at March 31, 2022 and December 31, 2021, respectively.

Two customers accounted for 100% of the Company’s consolidated contract assets at March 31, 2022 and December 31, 2021.

5.

(Loss) Income Per Share

The following table summarizes data by industry segment:presents a reconciliation between basic and diluted net (loss) income per share:

 

At and for the Three Months Ended September 30, 2017 Body Worn Devices  Hearing Health Direct-to-Consumer  Total 
Revenue, net $22,271  $1,763  $24,034 
Income (loss) from continuing operations  1,121   (204)  917 
Identifiable assets (excluding goodwill)  29,883   5,404   35,287 
Goodwill  9,551   1,004   10,555 
Depreciation and amortization  506   48   554 
Capital expenditures  350   16   366 
  

Three Months Ended

 
  

March 31, 2022

  

March 31, 2021

 
         

Net (loss) income

 $(597) $672 

Less: Income (loss) allocated to non-controlling interest

  60   (42)

Net (loss) income attributable to Intricon shareholders

 $(657) $714 
         
         

Basic – weighted shares outstanding

  9,256   8,994 

Weighted shares assumed upon exercise of stock awards

  0   613 

Diluted – weighted shares outstanding

  9,256   9,607 
         

Basic (loss) income per share attributable to Intricon shareholders:

 $(0.07) $0.08 

Diluted (loss) income per share attributable to Intricon shareholders:

 $(0.07) $0.07 

Net (loss) income per common share was based on the weighted average number of common shares outstanding during the periods when computing basic net income per share. Stock options are dilutive when the average market price of Company stock exceeds the exercise price of the potentially dilutive options. When dilutive, stock options are included as equivalents using the treasury stock method when computing diluted net income per share. Unvested shares represented by RSUs are also included in the dilution calculation, net of assumed proceeds and equivalent share repurchases. The Company excluded all stock awards outstanding in 2022 from the computation of the diluted loss per share because their effect would be anti-dilutive.

 


At and for the Nine Months Ended September 30, 2017 Body Worn Devices  Hearing Health Direct-to-Consumer  Total 
Revenue, net $61,495  $4,588  $66,083 
Income (loss) from continuing operations  1,736   (1,085)  651 
Identifiable assets (excluding goodwill)  29,883   5,404   35,287 
Goodwill  9,551   1,004   10,555 
Depreciation and amortization  1,500   159   1,659 
Capital expenditures  836   148   984 

6.

Income Taxes

 

Income tax expense for the three months ended March 31, 2022 was $15 compared to $90 for the same period in 2021. The Company has net operating loss carryforwards for U.S. federal income tax purposes. The Company has recorded a full valuation allowance against US deferred tax assets as of March 31, 2022.

The following was the (loss) income before income taxes for each jurisdiction in which the Company has operations for the period:

  

Three Months Ended

 
  

March 31, 2022

  

March 31, 2021

 

United States

 $(726) $585 

Singapore

  89   138 

Indonesia

  28   21 

Germany

  27   18 

(Loss) income before income taxes

 $(582) $762 

11

5.

7.

Geographic Information

Selected Balance Sheet Data

Inventories:

Inventories consisted of the following at:

  

Raw materials

  

Work-in process

  Finished products and components  

Total

 

March 31, 2022

                

Domestic

 $15,940  $1,478  $2,646  $20,064 

Foreign

  6,985   1,176   213   8,374 

Total

 $22,925  $2,654  $2,859  $28,438 
                 

December 31, 2021

             

Domestic

 $15,201  $760  $1,892  $17,853 

Foreign

  5,579   747   277   6,603 

Total

 $20,780  $1,507  $2,169  $24,456 

12

Property, Plant and Equipment Geographic Information:

 

The geographical distribution of long-lived assets to geographical areas consistednet of the following at:accumulated depreciation, consisting of machinery and equipment is set forth below:

 

 

March 31,

 

December 31,

 
 September 30, 2017 December 31, 2016  

2022

  

2021

 
United States $4,570  $4,640  $12,603  $12,337 
Singapore  1,195   1,413  1,273  1,346 
Other – primarily United Kingdom and Indonesia  523   553 

Other

  963   154 
Consolidated $6,288  $6,606  $14,839  $13,837 

 

Long-lived assets consist of propertymachinery and equipment.equipment with useful lives from three to twelve years. Excluded from long-lived assets are investments in partnerships, patents, license agreementsgoodwill, intangible assets, operating lease right-of-use (ROU) assets and goodwill.certain other assets. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to assureensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets.

 

The geographical distribution of net sales to geographical areas for the three and nine months ended September 30, 2017 and 2016 were as follows:

  Three Months Ended  Nine Months Ended 
  September 30, 2017  September 30, 2016  September 30, 2017  September 30, 2016 
United States $19,605  $11,201  $52,804  $35,154 
Europe  2,317   2,706   7,102   8,523 
Asia  1,740   1,380   5,541   5,918 
All other countries  372   283   636   667 
Consolidated $24,034  $15,570  $66,083  $50,262 

Geographic net sales are allocated based on the location of the customer.Intangible Assets:

 

For the three and nine months ended September 30, 2017, one customer accounted for 51% and 49%, respectively, of the Company’s consolidated net sales. For both the three and nine months ended September 30, 2016, one customer accounted for 38% and 39%, respectively, of the Company’s consolidated net sales.

At September 30, 2017, two customers combined accounted for 23% of the Company’s consolidated accounts receivable. At December 31, 2016, two customers combined accounted for 31% of the Company’s consolidated accounts receivable.


6.Inventories

InventoriesDefinite-lived intangible assets consisted of the following at:

 

   Raw materials  Work-in process  Finished products and components  Total 
September 30, 2017                 
Domestic  $6,334  $1,577  $3,150  $11,061 
Foreign   2,125   810   903   3,838 
Total  $8,459  $2,387  $4,053  $14,899 
                  
December 31, 2016                 
Domestic  $5,731  $1,324  $2,609  $9,664 
Foreign   1,751   284   644   2,679 
Total  $7,482  $1,608  $3,253  $12,343 
  

March 31, 2022

 
  

Gross Carrying Amount

  

Accumulated Amortization

  

Net Carrying Amount

 

Customer list

 $6,400  $(1,467) $4,933 

Technology intangibles

  7,070   (3,408)  3,662 

Total

 $13,470  $(4,875) $8,595 

 

  

December 31, 2021

 
  

Gross Carrying Amount

  

Accumulated Amortization

  

Net Carrying Amount

 

Customer list

 $6,400  $(1,267) $5,133 

Technology intangibles

  6,946   (3,080)  3,866 

Total

 $13,346  $(4,347) $8,999 

The customer list was established as a part of purchase accounting related to our EMS acquisition in 2020. The estimated useful life is eight years.

The technology intangibles provide the Company with wireless and self-fitting hearing aid technology and are being amortized based on estimated useful lives between five and seven years.

13

Investment in Partnerships:

Investment in partnerships consisted of the following:

  

March 31,

  

December 31,

 
  

2022

  

2021

 

Investment in Signison

 $361  $226 

Other

  235   247 

Total

 $596  $473 

The Company has a 50% ownership interest in Signison, a German based Company specializing in hearing health services. This is accounted for in the Company’s condensed consolidated financial statements using the equity method for all periods presented.

Contingent Consideration Liabilities:

Contingent consideration for the Emerald Medical Services earnout liability consisted of the following:

Carrying amount at December 31, 2020

 $3,574 

Change in fair value

  (739)

Less payments

  (1,052)

Carrying amount at December 31, 2021

 $1,783 

Change in fair value

  38 

Carrying amount at March 31, 2022

 $1,821 

The total earnout liability is included in other accrued liabilities and other long-term liabilities proportionately to when the liability is due.

Other Accrued Liabilities:

Other accrued liabilities consisted of the following at:

  

March 31, 2022

  

December 31, 2021

 

Pension and postretirement benefit obligations

 $177  $177 

Deferred revenue

  251   141 

Current technology intangible liability

  623   493 

Current earn-out contingent consideration liability

  161   148 

Customer funded projects

  728   340 

TCPA litigation accrual (Note 11)

  0   1,300 

Accrued corporate expenses

  991   237 

Other

  1,278   982 

Total

 $4,209  $3,818 

The technology intangible liability, reflected above, relates to amounts owed in relation to the Company’s wireless and self-fitting hearing aid technologies.

The earn-out liability is contingent on certain future events and is measured at fair value based on various level 3 inputs and assumptions including forecasts, probabilities of payment and discount rates. Amounts are classified as current if expected to be paid within the next twelve months. The liability for contingent consideration is subject to fair value adjustments each reporting period that will be recognized through the condensed consolidated statement of operations.

Other Long-Term Liabilities:

Other long-term liabilities consisted of the following at:

  

March 31,

  

December 31,

 
  

2022

  

2021

 

Noncurrent technology intangible liability

 $0  $541 

Noncurrent earn-out contingent consideration liability

  1,660   1,635 

Litigation liability

  540   709 

Other

  247   215 

Total

 $2,447  $3,100 

As of March 31, 2022, the Company had no debt under its existing credit facilities and was in compliance with all applicable covenants.

14

7.

8.

Short and Long-Term Debt

Investment Securities

 

ShortThe Company invests in commercial paper, corporate notes and long-term debt is summarizedbonds with original maturities of less than two years. The Company classifies these investments as held to maturity based on our intent and ability to hold these investments until maturity. As a result, these investments are recorded at amortized cost, which approximates fair value, using level 2 inputs.

The maturity dates of our investments as of March 31, 2022 are as follows:

 

  September 30, 2017  December 31, 2016 
Domestic Asset-Based Revolving Credit Facility $1,755  $3,218 
Note Payable  2,000   2,000 
Foreign Overdraft and Letter of Credit Facility  1,256   1,243 
Domestic Term-Loan  4,500   5,250 
Unamortized Finance Costs  (86)  (81)
Total Debt  9,425   11,630 
Less: Current Maturities  (2,411)  (2,346)
Total Long-Term Debt $7,014  $9,284 
  

Less than one year

  

1-5 years

  

Total

 

Commercial Paper Original Maturities of 91 Days or More

 $9,492  $-  $9,492 

Corporate Notes and Bonds

  5,965   4,551   10,516 

Total Investments

 $15,457  $4,551  $20,008 

 

Domestic Credit FacilitiesThe maturity dates of our investments as of December 31, 2021 are as follows:

  

Less than one year

  

1-5 years

  

Total

 

Commercial Paper Original Maturities of 91 Days or More

 $10,987  $0  $10,987 

Corporate Notes and Bonds

  8,433   4,558   12,991 

Total Investments

 $19,420  $4,558  $23,978 

 

The Company also maintains excess funds within level 1 money market accounts included within cash and its domestic subsidiaries are parties to a credit facility with The PrivateBankcash equivalents. Cash available in our money market accounts at March 31, 2022 and Trust Company. The credit facility, as amended through September 30, 2017, provides for:December 31, 2021 was $1,882 and $2,943, respectively.

 

9.

a $9,000 revolving credit facility, with a $200 sub facility for letters of credit. Under the revolving credit facility, the availability of funds depends on a borrowing base composed of stated percentages of the Company’s eligible trade receivables and eligible inventory, and eligible equipment less a reserve; and

Leases

a term loan in the original amount of $6,000.

 

On March 9, 2017,The Company’s leases pertain primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one year or more. The Company has three leased facilities in Minnesota, one that expires in 2022,one that expires in 2023,one that expires in 2027,one leased facility in California that expires in 2024,one leased facility in Singapore that expires in 2025,one leased facility in Indonesia that expires in 2027, and one leased facility in Germany that expires in 2022. Additionally, the Company has two short term leases with initial terms of less than one year. One short term leased facility is located in Illinois and its domestic subsidiary, IntriCon, Inc., entered into a Tenth Amendment to the Loan and Security Agreement and Waiver (the “Tenth Amendment”) with The PrivateBank and Trust Company. The Tenth Amendment, among other things:

amended the minimum EBITDA (as defined in the Loan and Security Agreement), funded debt to EBITDA ratio and fixed charge coverage ratio covenants; and


waived defaults in the funded debt to EBITDA ratio and fixed charge coverage ratio covenants as of December 31, 2016.

All of the borrowings under this agreement have been characterized as either a current or long-term liability on our balance sheetsecond facility is in accordance with the repayment terms described more fully below.California. 

 

Weighted average interestCertain foreign leases allow for variable lease payments that depend on the revolving credit facility was 7.11%an index or a market rate adjustment for the nine months ended September 30, 2017respective country and are adjusted on an annual basis. The adjustment is recognized as incurred in the condensed consolidated statement of operations. The facility leases include options to extend for terms ranging from one year to five years. Lease options that the Company is reasonably certain to execute are included in the determination of the ROU asset and lease liability. The Company also leases equipment that include bargain purchase options at termination. These leases have been classified as finance leases.

As of March 31, 2022, the Company has a weighted-average lease term of 0.2 years for its finance leases, and 3.7 years for its operating leases. As of March 31, 2022, the Company has a weighted-average discount rate of 5.56% for its finance leases and 4.82% for the year ended its operating leases. As of December 31, 2016. The outstanding balance of the revolving credit facility was $1,755 and $3,218 at September 30, 2017 and December 31, 2016, respectively. The total availability on the revolving credit facility was approximately $5,632 and $5,121 at September 30, 2017 and December 31, 2016, respectively.

The outstanding principal balance of the term loan, as amended, is payable in quarterly installments of $250. Any remaining principal and accrued interest is payable on February 28, 2019. IntriCon is also required to use 100% of the net cash proceeds of certain asset sales (excluding inventory and certain other dispositions), sale of capital securities or issuance of debt to pay down the term loan.

The Company was in compliance with the financial covenants under the facility as of September 30, 2017.

Foreign Credit Facility

In addition to its domestic credit facilities, the Company’s wholly-owned subsidiary, IntriCon, PTE LTD., entered into an international senior secured credit agreement with Oversea-Chinese Banking Corporation Ltd. that provides for an asset based line of credit. Borrowings bear interest at a rate of .75% to 2.5% over the lender’s prevailing prime lending rate. Weighted average interest on the international credit facilities was 3.95% and 3.50% for the nine months ended September 30, 2017 and the year ended December 31, 2016. The outstanding balance was $1,256 and $1,243 at September 30, 2017 and December 31, 2016, respectively. The total remaining availability on the international senior secured credit agreement was approximately $524 and $455 at September 30, 2017 and December 31, 2016, respectively.

Note Payable

HHE has a $2,000 note payable to the party holding 80% of its equity interest. The note is secured by substantially all of the assets of HHE. The note is payable over 48 months in quarterly installments with interest at 5% per year, except that interest only will be paid in the first twelve months, with the deferred payments to be made at maturity.

8.Income Taxes

Income tax expense for the three and nine months ended September 30, 2017 was $47 and $165 compared to $33 and $119, respectively, for the same periods in 2016. The expense was primarily due to foreign operations. The Company has net operating loss carryforwards for U.S. federal income tax purposes and, consequently, minimal federal or state benefit or expense from the domestic operations was recognized as the deferred tax asset has a full valuation allowance.

The following was the income (loss) before income taxes for each jurisdiction in which 2021, the Company has operationsa weighted-average lease term of 0.4 years for its finance leases, and 3.3 years for its operating leases. As of December 31, 2021, the Company has a weighted-average discount rate of 5.56% for its finance leases, and 4.98% for its operating leases. Operating cash flows for the threeperiod ended March 31, 2022, and nine months ended September 30, 20172021 from operating leases were $585 and 2016.$609, respectively. Financing lease assets are classified as property, plant and equipment within the condensed consolidated balance sheet.

 

  Three Months Ended  Nine Months Ended 
  September 30, 2017  September 30, 2016  September 30, 2017  September 30, 2016 
United States $1,008  $(1,250) $1,049  $(2,664)
Singapore  245   212   168   779 
Indonesia  20   18   54   54 
United Kingdom  (184)  (191)  (595)  (490)
Germany  (125)  99   140   314 
Income (loss) before income taxes and discontinued operations $964  $(1,112) $816  $(2,007)

 


15

The following tables summarizes lease costs by type:

  

Three Months Ended

 
  

March 31, 2022

  

March 31, 2021

 

Lease cost

        

Finance lease cost:

        

Amortization of right-of-use assets

 $2  $10 

Interest on lease liabilities

  0   1 
         

Operating lease cost

  581   582 

Variable lease cost

  90   120 

Total lease cost

 $673  $713 

Maturities of lease liabilities are as follows as of March 31, 2022:

  

Operating Leases

  

Financing Leases

  

Total

 

2022

 $1,722  $1  $1,723 

2023

  1,783   0   1,783 

2024

  1,493   0   1,493 

2025

  1,331   0   1,331 

2026 and thereafter

  631   0   631 

Total lease payments

  6,960   1   6,961 

Less: Interest

  (606)  0   (606)

Present value of lease liabilities

 $6,354  $1  $6,355 

9.

10.

Shareholders’

Shareholders Equity and Stock-based Compensation

 

The Company has a 2006 Equity Incentive Plan and a an Amended and Restated 2015 Equity Incentive Plan. The 2015 plan, which was approved by the shareholders on April 24, 2015, Equity Incentive Plan replaced the 2006 Equity Incentive Plan and new plan. New grants may not be made under the 2006 Plan. plan; however certain option grants under the 2006 plan remain exercisable as of March 31, 2022.

 

Under the 2015 Equity Incentive Plan, the Company may grant stock options, stock awards, stock appreciation rights, restricted stock units (“RSUs”), performance restricted stock units (“PRSUs”) and other equity-based awards, although no such awards, other than stock options, had been granted as of September 30, 2017.awards. Under all awards, the terms are fixed on the grant date. Generally,The 2015 plan was amended and restated in 2020 to reflect certain corporate governance changes and to increase the exercisenumber of shares of common stock that could be awarded under the 2015 plan by 500 shares, subject to shareholder approval, which was obtained on May 4, 2021.

For the three months ended March 31, 2022, the Company granted a total of 103 RSUs and 38 PRSUs at a weighted average closing price of stock options equals the market price of the Company’s stock$16.51 on the date of the grant.grant. The RSUs vest in equal, annual installments over a three year period beginning on the first anniversary of the date of grant at which time common stock is issued with respect to vested units. Outstanding PRSUs will vest depending upon the achievement of total revenue in specific markets during 2023 or 2024 as applicable, at a threshold level (below which no PRSUs will vest), a target level and a maximum level (at which the maximum number of PRSUs will vest). 

The Company has also historically granted stock options under the plans. For the three months ended March 31, 2022, and 2021, the Company did not grant any options. Options granted under the plans generally vest in equal, annual installments over a three years, year period beginning on the first anniversary of the date of grant and have a maximum term of 10 years. During the three months ended March 31, 2022, 15options were forfeited in order to cover the exercise price of the options.

 

The Compensation Committee

16

Stock award activity as of Directors has established a non-employee directors’ stock fee election program, referred to as the director’s program, and a non-employee director and executive officer stock purchase program, referred to as the management purchase program, as an award under the 2015 Plan. There were no shares purchased under the director program or the management purchase program during the three and nine months ended September 30, 2017 and 2016.

Stock option activity during the nine months ended September 30, 2017March 31, 2022 was as follows:

 

  Number of Shares  Weighted-average Exercise Price  Aggregate Intrinsic Value 
Outstanding at December 31, 2016  1,385  $6.54     
Options forfeited or cancelled  (5)  7.36     
Options granted  222   7.36     
Options exercised  (69)  5.50     
             
Outstanding at September 30, 2017  1,533  $6.71  $8,566 
             
Exercisable at September 30, 2017  1,118  $6.52  $6,539 
             
Available for future grant at December 31, 2016  404         
             
Available for future grant at September 30, 2017  189         
  

Outstanding Awards

         
  

Stock Options

  

RSUs

  

Total

  Stock Option Weighted-Average Exercise Price (a)  

Aggregate Intrinsic Value

 
                     

Outstanding at December 31, 2021

  547   217   764  $6.69     

Awards granted

  -   141   141   -     

Awards exercised or released

  (91)  (50)  (141)  6.40     

Outstanding at March 31, 2022

  456   308   764  $6.75  $15,159 
                     

Exercisable at March 31, 2022

  456       456  $6.75  $7,800 
                     

Available for future grant at December 31, 2021

          497         
                     

Available for future grant at March 31, 2022

          352         

(a) The weighted average exercise price calculation does not include outstanding RSUs

 

The number of shares available for future grants at September 30, 2017March 31, 2022 does not include a total of up to 1,084 139 shares subject to options outstanding under the 2006 Equity Incentive Plan, which will become available for grant under the 2015 Equity Incentive Plan as outstanding options under the 2006 Equity Incentive Plan expire, terminate, are cancelled or forfeited or are withheld in the event of the expiration, cancellation or surrendera net exercise of such options.

 

The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of subjective assumptions, including the expected stock price volatility. Because the Company’s options have characteristics different from those of traded options, in the opinion of management, the existing models do not necessarily provide a reliable single measure of the fair value of its options. The weighted average exercise price of options granted was $7.05 and $7.36 for options granted during the three and nine months ended September 30, 2017. The weighted average exercise price of options granted was $7.14 for options granted during the nine months ended September 30, 2016.

The Company calculates expected volatility for stock options and awards using the Company’s historical volatility.


The Company currently estimates a zero percent forfeiture rate for stock options, but will continue to review this estimate in future periods.

The risk-free rates for the expected terms of the stock options and awards are based on the U.S. Treasury yield curve in effect at the time of grant.

The weighted average remaining contractual life of options exercisable at September 30, 2017 was 4.02 years.

The Company recorded $209 and $634$481 of non-cash stock optioncompensation expense for the three and nine months ended September 30, 2017, respectively. The Company recorded $159 and $506 of non-cash stock option expenseMarch 31, 2022 compared to $453 for the three and nine months ended September 30, 2016, respectively.same period in 2021. As of September 30, 2017,March 31, 2022, there was $1,198$3,984 of total unrecognized compensation costs related to non-vested stock option and RSU awards that are expected to be recognized over a weighted-average period of 1.952.0 years. The total intrinsic value of options exercised during the three months ended March 31, 2022 was $1,045.

 

The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through September 30, 2017,March 31, 2022, provides that a maximum of 300 shares may be sold under the Purchase Plan. There were 3 and 102 shares purchased under the plan for the three and nine months ended September 30, 2017, respectively, March 31, 2022 and a total of 5 and 14 shares purchased for the three and nine months ended September 30, 2016, respectively.2021.

 

17

10.

11.

Income (Loss) Per Share

Legal Proceedings

 

The following table presents a reconciliation between basic and diluted earnings per share:Asbestos Litigation

  Three Months Ended  Nine Months Ended 
  September 30, 2017  September 30, 2016  September 30, 2017  September 30, 2016 
Numerator:            
Income (loss) from continuing operations before discontinued operations $917  $(1,145) $651  $(2,126)
Loss on sale of discontinued operations        (164)   
Loss from discontinued operations, net of income taxes     (194)  (128)  (759)
Net income (loss)  917   (1,339)  359   (2,885)
                 
Less: loss allocated to non-controlling interest  (186)  (35)  (925)  (106)
                 
Net income (loss) attributable to shareholders $1,103  $(1,304) $1,284  $(2,779)
                 
Denominator:                
Basic – weighted shares outstanding  6,853   6,796   6,836   6,287 
Weighted shares assumed upon exercise of stock options  398      343    
Diluted – weighted shares outstanding  7,251   6,796   7,179   6,287 
                 
Basic income (loss) per share attributable to IntriCon shareholders:                
Continuing operations $0.16  $(0.16) $0.23  $(0.32)
Discontinued operations     (0.03)  (0.04)  (0.12)
Net income (loss) per share: $0.16  $(0.19) $0.19  $(0.44)
                 
Diluted income (loss) per share attributable to IntriCon shareholders:                
Continuing operations $0.15  $(0.16) $0.22   (0.32)
Discontinued operations     (0.03)  (0.04)  (0.12)
Net income (loss) per share: $0.15  $(0.19) $0.18  $(0.44)


The dilutive impact summarized above relates to the periods when the average market price of Company stock exceeded the exercise price of the potentially dilutive option securities granted. Earnings per common share was based on the weighted average number of common shares outstanding during the periods when computing the basic earnings per share. When dilutive, stock options are included as equivalents using the treasury stock method when computing the diluted earnings per share. Individual components of basic and diluted income (loss) per share may not sum to the total income (loss) per share due to rounding.

Excluded from the computation of diluted earnings per share for the three and nine months ended September 30, 2016 were outstanding in the money options to purchase approximately 73 and 161 common shares, respectively, because the effect would have been anti-dilutive due to the Company’s net loss in the period.

11.Legal Proceedings

 

The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may have contracted asbestos-related diseases as a result of exposure to asbestos products or equipment containing asbestos sold by one or more named defendants. These lawsuits relate to the discontinued heat technologies segment which was sold in March 2005. Due to the non-informative nature of the complaints, the Company does not know whether any of the complaints state valid claims against the Company. Certain insurance carriers have informed the Company that the primary policies for the period August 1, 1970-19781970-1978 have been exhausted and that the carriers will no longer provide defense and insurance coverage under those policies. However, the Company has other primary and excess insurance policies that the Company believes afford coverage for later years. Some of these other primary insurers have accepted defense and insurance coverage for these suits, and some of them have either ignored the Company’s tender of defense of these cases, or have denied coverage, or have accepted the tenders but asserted a reservation of rights and/or have advised the Company that they need to investigate further. In addition, some of the primary and excess insurers have gone out of business, and thus coverage is not available. There are also primary policies for years earlier than 1970 that were purchased by the Company, and coverage under those policies will be investigated. Because settlement payments are applied to all years a litigant was deemed to have been exposed to asbestos, the Company believes that it will have funds available for defense and insurance coverage under the non-exhausted primary and excess insurance policies. However, unlike the older policies, the more recent policies have deductible amounts for defense and settlements costs that the Company will be required to pay; accordingly, the Company expects that its litigation costs will increase in the future. Further, manymost of the policies covering later years (approximately 1984 and thereafter) have exclusions for any asbestos products or operations, and thus do not provide insurance coverage for asbestos-related lawsuits. The Company does not believe that the asserted exhaustion of some of the primary insurance coverage for the 1970-19781970-1978 period will have a material adverse effect on its financial condition, liquidity, or results of operations. Management believes that the number of insurance carriers involved in the defense of the suits, and the significant number of policy years and policy limits under which these insurance carriers are insuring the Company, make the ultimate disposition of these lawsuits not material to the Company’sCompany's consolidated financial position or results of operations. As of March 31, 2022, we recorded $120 and $540 within other accrued liabilities and other long-term liabilities, respectively, within our condensed consolidated balance sheet for estimated future claims. An insurance receivable of $120 and $540 was recorded within other current assets and other assets, net, respectively, within our condensed consolidated balance sheet as of March 31, 2022 for estimated insurance recoveries.

TCPA Litigation

On October 9, 2019, plaintiff Mark Hoffman (“Hoffman”) filed a putative class action lawsuit against defendant Hearing Help Express, Inc. (“HHE”), a subsidiary of the Company, in the Federal District Court for the Western District of Washington (the “Court”) alleging violations of the federal Telephone Consumer Protection Act (“TCPA”). HHE’s investigation revealed third-party lead generator Triangular Media Corp. (“Triangular”) provided Hoffman’s information to HHE. Hoffman claims he did not provide the requisite prior express written consent for autodialed telemarketing calls regarding hearing aids to be placed to his cellphone. He also claims he did not provide the requisite permission for telemarketing calls to his number registered on the Do-Not-Call (“DNC”) registry. Since the initial complaint was filed, Hoffman amended his complaint several times to add additional parties, including Triangular, Triangular’s alleged owner, an alleged entity related to Triangular called LeadCreations.Com, LLC, Intricon, Inc., and Intricon Corporation. With respect to HHE, Hoffman sought to certify a class of certain automated outbound telemarketing calls HHE allegedly made without prior consent and calls made to numbers on the DNC registry, in the last four years. Hoffman also sought to hold the Company vicariously liable for all of the calls HHE made without prior consent. The potential exposure under the TCPA is $500 per call, or $1,500 per call if the violation is deemed willful or knowing.

On July 26, 2021, the Company and the other defendants entered into a Class Action Settlement and Release ("Settlement Agreement") with Hoffman for himself and on behalf of the settlement class relating to this matter. In entering into the Settlement Agreement, the Company and the other defendants are making no admission of liability. The Settlement Agreement was submitted to the Court for preliminary approval on July 28, 2021, which was granted. The Court set a fairness and final approval hearing for January 5, 2022.

Pursuant to the Settlement Agreement, among other things, (a) the Company agreed to pay total cash consideration of $1.3 million into a settlement fund, and (b) Hoffman and the settlement class members agreed to a release of claims against the Company, Intricon, Inc. and HHE relating to any claim or potential claim relating to the marketing activities described in the complaint. The class members releasing claims include any person who received, on or after October 9, 2015, a non-emergency telephone call from or on behalf of HHE and whose contact information was received either directly or indirectly from Triangular (or its purported affiliated entity, LeadsCreations) and one other vendor who supplied phone numbers to HHE.

On January 5, 2022, the parties attended the Final Approval Hearing with the Court on the class settlement. The Court granted the motion for final approval of the class settlement and Plaintiff's Motion for Attorneys' Fees, Costs, and Service Payment. The deadline to file a notice of appeal was February 4, 2022; no appeal was filed by that date, the Settlement Agreement became effective and the $1.3 million settlement fund payment was paid. The release will be effective as to all class members who did not validly opt out of the class, regardless of whether they file a claim form and receive a payment.

Litigation Related to the Merger

Between April 14, 2022 and May 5, 2022, six lawsuits were filed against the Company and its directors: Stein v. Intricon Corporation, et al., 1-22-cv-03099-PGG in the United States District Court for the Southern District of New York; Sandoval v. Intricon Corporation, et al., 2:22-cv-01512 in the United States District Court for the Eastern District of Pennsylvania (the “Sandoval Complaint”); Waterman v. Intricon Corporation, et al., 2:22-cv-01541-GAM in the United States District Court for the Eastern District of Pennsylvania; Whitfield v. Intricon Corporation, et al., 1:22-cv-02261-EK-LB in the United States District Court for the Eastern District of New York . ; Raul v. Intricon Corporation, et al., 1:22-cv-03638 in the United States District Court for the Southern District of New York; and Finger v. Intricon Corporation, et al., 1:22-cv-03648 in the United States District Court for the Southern District of New York.

 

The complaints generally allege that the Company’s former French subsidiary, Selas SAS,Preliminary Proxy Statement filed for insolvency in France. The Company may be subject to additional litigation or liabilities aswith the SEC on April 12, 2022 omitted material information that rendered it false and misleading. As a result of the French insolvency proceeding,alleged omissions, the lawsuits seek to hold the Company and its directors liable for violating Section 14(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 14a-9 promulgated thereunder, and additionally seek to hold the Company’s directors liable as control persons pursuant to Section 20(a) of the Exchange Act. The Sandoval Complaint also alleges that the Company’s directors violated their fiduciary duties of care, loyalty and good faith, and that the Company aided and abetted the directors’ breach of their fiduciary duties.  The complaints variously seek, among other relief, an injunction preventing the closing of the Merger, rescission of the Merger (in case the Merger is consummated) or awarding of rescissory damages, declaring the Merger Agreement unenforceable, and awarding of damages and an award of costs of the lawsuit, including liabilities under guarantees aggregating approximately $460.reasonable allowance for plaintiffs’ attorneys’ and experts’ fees.

The Company believes that the lawsuits are without merit and intends to defend them vigorously.

In addition, between May 4, 2022 and May 6, 2022, the Company received three demand letters from alleged shareholders pursuant to 15 Pa.C.S. §1308 to inspect books and records of the Company relating to, among other things, the Merger Agreement and the Merger.  The Company intends to review the demand letters and respond appropriately.  The Company cannot determine at this time if the books and records demands will lead to litigation.

Other Litigation Matters

 

The Company is also involved from time to time in other lawsuits arising in the normal course of business. While it is not possible to predict with certainty the outcome of these matters, management is of the opinion that the disposition of these lawsuits and claims will not materially affect ourthe Company’s consolidated financial position, liquidity, or results of operations.

 

12.Related-Party Transactions
18

 

One of the Company’s subsidiaries leases office and factory space from a partnership consisting of one present and two former officers of the subsidiary, including Mark Gorder, a member of the Company’s Board of Directors and the President and Chief Executive Officer of the Company. The subsidiary is required to pay all real estate taxes and operating expenses. The total base rent expense, real estate taxes and other charges incurred under the lease were approximately $124 and $372 for the three and nine months ended September 30, 2017, respectively, and approximately $121 and $364 for the three and nine months ended September 30, 2016, respectively. The term of the lease runs to January 31, 2022. The partnership sold the property to an unaffiliated third party on October 13, 2017.

 


The Company uses the law firmITEM 2. Management's Discussion and Analysis of Blank Rome LLP for legal services. A partnerFinancial Condition and Results of that firm is the son-in-law of the Chairman of the Company’s Board of Directors. For the three and nine months ended September 30, 2017, the Company paid that firm approximately $29 and $94, respectively, for legal services and costs. For the three and nine months ended September 30, 2016, the Company paid that firm approximately $50 and $183, respectively, for legal services and costs. The Chairman of our Board of Directors is considered independent under applicable Nasdaq and Securities and Exchange Commission rules because (i) no payments were made to the Chairman or the partner directly in exchange for the services provided by the law firm and (ii) the amounts paid to the law firm did not exceed the thresholds contained in the Nasdaq standards. Furthermore, the aforementioned partner does not provide any legal services to the Company and is not involved in billing matters.Operations

The Company has a 50% ownership in Signison, which is a German based hearing health company. Signison owes the Company a note receivable balance of $465 as of September 30, 2017.

13.Revenue by Market

 

The following tables set forth,management discussion and analysis (“MD&A”) provides information that the Company believes is useful in better understanding the operating results, cash flows and financial condition of the Company. Quantitative information is provided about the material revenue and expense drivers as well as any other significant factors we believe are useful for understanding our results. The MD&A should be read in conjunction with both the periods indicated, net revenue by market:

  Three Months Ended  Nine Months Ended 
  September 30, 2017  September 30, 2016  September 30, 2017  September 30, 2016 
             
Medical $14,840  $8,814  $39,904  $27,832 
Hearing Health  5,816   4,927   17,086   16,722 
Hearing Health Direct-to-Consumer  1,763      4,588    
Professional Audio Communications  1,615   1,829   4,505   5,708 
Total Revenue $24,034  $15,570  $66,083  $50,262 

ITEM 2.condensed consolidated financial information and related notes included in this Form 10-Q, and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2021. This discussion contains various “Non-GAAP Financial Measures��� and also contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Information and Cautionary Statements” located at the end of Item 2 of this report.

 

Business Overview

 

Headquartered in Arden Hills, Minnesota, IntriConIntricon Corporation (together with its subsidiaries referred toherein as the “Company”, “IntriCon,”or “Intricon”, “we”, “us” or “our”) is an international company engaged in designing, developing, engineering, manufacturingjoint development manufacturer (“JDM”) of micromedical components, sub-assemblies and distributing body-wornfinal devices. In addition to its operations in Minnesota, the Company has facilities in Illinois, Singapore, Indonesia, Germany and the United Kingdom.

In December 2016, the Company’s Board of Directors approved plans to discontinue its cardiac diagnostic monitoring business. The Company sold the cardiac diagnostic monitoring business on February 17, 2017serves as a JDM partner to Datrix, LLC. For all periods presented, the Company classified this business as discontinued operations, and, accordingly, has reclassified historical financial data presented herein.

The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity.

On January 19, 2017, the Company announced that it had exercised its option to acquire the remaining 80 percent stake in HHE. The transaction is expected to close in the fourth quarter of 2017. The results of HHE were consolidated into the Company’s financial statements beginning October 31, 2016. The Company allocates income and losses to the noncontrolling interest based on current ownership percentage, however, as part of the closing, IntriCon will likely absorb a portion of the losses previously allocated to the majority owner. The amount of losses previously allocated to the majority owner that we may have to absorb could range $500,000 and $700,000. Losses incurred by HHE to date include non-cash amortization, acquisition related costs and operating results, all of which are related to prior periods and have no future cash impact


In April 2017, the Company entered into an agreement to acquire a 49% stake in Soundperience for 1,200 Euros. As of September 30, 2017, the Company holds a 16% stake in Soundperience, which will increase to 49% upon the completion of certain milestones and payment of the purchase price for that equity. As of September 30, 2017, the Company has an equity investment and advance in Soundperience of $1,255. The Company does not anticipate the Soundperience business will have a notable financial impact on operating results, but rather will provide the company with exclusive access in the United States to critical software technology. Soundperience has designed self-fitting hearing aid technology. The Company’s self-fitting hearing aid technology is being used in the German market today, most notably through our Signison joint venture with the owner of Soundperience. Both Soundperience and Signison will be accounted for in the Company’s financial statements using the equity method.

Information contained in this section of this Quarterly Report on Form 10-Q and expressed in U.S. dollars is presented in thousands (000s), except for per share data and as otherwise noted.

Market Overview

IntriCon serves the body-wornleading medical device marketoriginal equipment manufacturers (“OEMs”) by designing, developing, engineering, manufacturing, packaging and distributing micro-miniaturemicromedical products for high growth markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. Our mission is to improve, extend and save lives by advancing innovative micromedical technologies through joint development and manufacturing partnerships with industry leading medical device companies.

Market Overview

Intricon serves as a JDM to leading medical device OEMs by designing, developing, engineering, manufacturing, packaging and distributing micromedical products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the medical bio-telemetry market, the emerging value based hearing healthcare market, the hearing health direct to consumer market and the professional audio communication market.solutions. Revenue from these markets is reported on the respective diabetes, other medical, hearing health value based direct-to-end-consumer (DTEC), hearing health direct to consumervalue based indirect-to-end-consumer (ITEC), hearing health legacy OEM, and professional audio linescommunications in the discussion of our results of operations in “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 133 “Revenue by Market”Recognition” to the Company’s condensed consolidated condensed financial statements included herein.

 

Value Based Hearing Healthcare MarketThe Company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete body-worn devices for leading and emerging medical device manufacturers. Intricon currently serves this market by offering medical device manufacturers the capabilities to design, develop, engineer, manufacture, package and distribute medical devices that are easier to use, smaller, lighter and use less power. Increasingly, the medical device industry is looking to outsource the manufacturing, assembly and packaging of their products.

 

The Company believes the value based hearing healthcare (VBHH) market offers significant growth opportunities. In the United States alone, there are approximately 37.5 million adults that report some degree of hearing loss. In adults, the most common cause of hearing loss is aging and noise. In fact, by the age of 65, one out of three peopleseveral factors have hearing loss. The hearing-impaired population is expected to grow significantly over the next decade due to an aging population and more frequent exposure to loud sounds that can cause noise-induced hearing loss. It is estimated that hearing aids can help more than 90 percent of people with hearing loss, however the current market penetration into the U.S. hearing impaired population is approximately 20 percent, a percentage that has remained essentially unchanged for the last four decades. The primary deterrents to greater penetration are cost and access. The average cost of a hearing aid in the US market today is over $2,400 per device, more than double the cost from twelve years ago. Approximately 70 percent of the hearing impaired have hearing loss in both ears (referred to as a binaural loss), driving the total cost to almost $5,000 on average for a set of hearing aids.

We believe a perfect vortex of factors has come together over the last few years to enable the emergence of a US market disruptivehigh-quality, low cost distribution model, including, value hearing aid. These factors include the continued consolidation of retail (causing escalating hearing aid prices), consumer outcry, consumer education, advancements in technology (such as behind-the-ear devices, advanced digital signal processing, low-power wireless, and self-fitting software) as well asand pending regulatory actions and pronouncements bychange to allow the U.S. Food and Drug Administration, the President’s Councilsale of Advisors on Science and Technology and the National Academies of Science, Engineering and Medicine.

Today in the US market, the conventional channel pushes allover-the-counter (“OTC”) hearing impaired through the same bloated, costly channel. However, a very large portion of the hearing-impaired market – mostly notably those with mild to moderate losses – could be properly served with the proper combination of high quality, outcome based devices, advanced fitting software and consumer services/care best practices – all at much lower cost. We believefundamental change is needed and are excited about the opportunity that we created through thoughtful hard work and planning: a chance to deliver superior outcomes-based affordable hearing healthcare, by combining state-of-the-art devices and software technology, along with best practices customer service and at a much lower cost directly to consumers across the country, many of whom have not been able to afford care previously.

In early January 2016, the U.S. Food and Drug Administration (FDA) weighed in on low hearing aid penetration rates with an announcement that highlighted statistics from the National Institute on Deafness and Other Communication Disorders. They found that 37.5 million U.S. adults aged 18 and older report some form of hearing loss. However, only 30 percent of adults over 70, and 16 percent of those aged 20 to 69, who could benefit from wearing hearing aids, have ever used them. Based on these statistics,aids. On October 19, 2021, the FDA reopened the public comment period onproposed a draft guidance relatedregulations to the agency’s premarket requirements for hearing aids and personal sound amplifiers (PSAPs). In April 2016, the FDA hostedestablish a public workshop to gather stakeholder and public input on draft guidance related to the agency’s premarket requirements for hearing aids and PSAPs. The FDA’s intent is to consider ways in which regulation can support further device penetration into the hearing market. In December 2016, the FDA announced important steps to better support consumer access to hearing aids. The agency issued a guidance document explaining that it does not intend to enforce the requirement that individuals age 18 and older receive a medical evaluation orsign a waiver prior to purchasing most hearing aids, effective immediately. It also announced its commitment to consider creating a category of over-the-counter (OTC) hearing aids that could deliver new innovative and lower-cost products to millions of consumers.


Furthermore, there have been significant public policy developments during 2017. On August 18, 2017, President Donald Trump signed into law H.R. 2430, the U.S. Food and Drug Administration (FDA) Reauthorization Act, which includes the Over-the-Counter (“OTC”) Hearing Aid Act of 2017. The legislation is designed to enable adults with mild- to moderate-hearing loss to access OTC hearing aids without being seen by a hearing care professional. The OTC Hearing Aid Act requires the FDA to create and regulate aregulatory category of OTC hearing aids that when finalized, would allow hearing aids to ensure they meetbe sold throughout the same high standards for safety, consumer labeling, and manufacturing protection that all othercountry directly to consumers in stores or online without a medical devices must meet. Additionally,exam or a fitting by a licensed practitioner, such as an audiologist.

To best approach this market opportunity, the OTC Hearing Aid Act mandates that the FDA establish an OTC hearing aid category for adults with “perceived” mild- to moderate-hearing loss within three years of passage of the legislation. The FDA also must finalize a rule within 180 days after the close of the comment period, detailing what level of safety, labeling and consumer protections will be included. We believe this legislationCompany has the potential to remove the significant barriers existing today that prevent innovative hearing health solutions. We believe that this legislation will invigorate competition, spur innovation and facilitate the development of an ecosystem of hearing health care that provides affordable and accessible solutions to millions of unserved or underserved Americans. Additionally, these public policy changes all further support our strategicsharpened its focus to gain direct accessidentify potential high-profile branding partners that value Intricon’s ability to consumersdeliver superior hearing aids, self-fitting software, and customer care to the underservedU.S. market.

 

The Company is committed to increasing investments to support its medical business development efforts. In early 2019, the Company hired a vice president of medical business development and in August 2021 the final stagesCompany hired a vice president of commercializing its PhysioLink™ 2 wireless technology, which will be incorporated into product platforms serving the traditionalresearch and value based hearing healthcare markets. This technology is an integrated platform that incorporates IntriCon’s Audion™ 8 amplifier and 2.4 GHz Bluetooth® low energy, enabling wireless connectivity from any Bluetooth® enabled device operating IntriCon’s propriety software over distances up to ten meters.

We are also currently developing our third generation PhysioLink™ technology, leveraging industry leading wireless IC technology to enable concurrent audio streaming and data transmission over Bluetooth® low energy. This technology will be incorporated into product platforms serving traditional and value based hearing healthcare markets, providing end users with an unprecedented experience through breakthrough audio and wireless performance.

In October of 2016, we purchased 20% of HHE, a direct-to-consumer mail order hearing aid provider. In January 2017, we exercised an option to acquire the remaining 80% equity interest and expect to close the transaction in the fourth quarter of 2017. HHE is a key next step in our value based hearing healthcare strategy. Over the last decade, we have invested in the technology and low-cost manufacturing to design and build superior devices and fitting solutions, to address what we estimate to be a $1 billion annually value based hearing healthcare market. With this acquisition, we believe we now have the channel infrastructure to directly reach consumers and—importantly for millions—the ability to offer high-quality hearing healthcare at a fraction of the cost. Through our other VBHH initiatives and tests, we have formed alliances with other key partners, which have given us experience and vital insight as we move aggressively into a more consumer-facing role. HHE provides an efficient, traditional direct-to-consumer channel to reach consumers who likely do not have insurance that will cover hearing devices. This is a channel that we can build on and expand via technology—and one that is complementary with many of our existing relationships.

In April 2017, we entered into an agreement to acquire a 49% stake in Soundperience. As of September 30, 2017, we hold a 16% stake in Soundperience, which will increase to 49% upon the completion of certain milestones and payment of the purchase price for that equity. Soundperience has designed self-fitting hearing aid technology. This company’s self-fitting hearing aid technology is being used in the German market today, most notably though our Signison joint venture with Soundperience.

Currently, the Soundperience technology is PC based and is wired to the hearing aid during programing. However, the system will be integrated with IntriCon’s wireless hearing aids over the next few months, and initially rolled out in Germany through our Signison joint venture.

We believe strongly that incorporating self-fitting technology is a critical step in creating our high-quality, low-cost hearing healthcare ecosystem. Soundperience’s technology has the potential to drastically reduce the price of hearing aids, drive greater access and increase customer satisfaction.


development. The Company alsoexpanded our core competencies and diversified our revenue base with the acquisition of EMS in 2020. The Company believes it has various international VBHH initiatives. On November 3, 2015, the Company acquired the assets of PC Werth through its IntriCon UK subsidiary to gain direct access to the NHS and to have greater control over its efforts to accelerate new market penetration into the United Kingdom. IntriCon UK has been appointed as a supplier to the NHS Supply Chain’s National Framework. The NHS is widely seen as the most efficient hearing aid delivery system in the world, supplying an estimated 1.4 million hearing aids annually. We believe IntriCon is well positionedsignificant opportunities to serve their needs, and we are developing new technologies to further enhance delivery efficiencies and product standards in the future.

We also believe there are niches in the conventional hearing health channel that will embrace our VBHH proposition in the United States and Europe. High costs of conventional devices and retail consolidation have constrained the growth potential of the independent audiologist and dispenser. We believe our software and product offering can provide independent audiologists and dispensers the ability to compete with larger retailers, such as Costco, and manufacturer owned retail distributors. In the third quarter of 2015, we announced a joint venture with The Academy of Doctors of Audiology (ADA) to provide hearing instruments and educational resources to audiologists and their patients. The joint venture operates as a limited liability company under the name “earVenture LLC”. EarVenture was officially launched in November 2015 at the ADA conference. To date, more than 400 of the 1,200 ADA members have registered to join the earVenture program and we have delivered initial units. In 2016, earVenture began rolling-out a comprehensive marketing and sales plan to convert those registered members to consistent customers, as well as solicit non-registered ADA members to join the program. While we do not view earVenture, near term, as a meaningful contributor to sales, it continues to provide valuable industry insights and has the potential for future value by connecting it to our emerging direct-to-consumer channel.

Medical Bio-Telemetry

In the medical bio-telemetry market, the Company is focused on sales of bio-telemetry devices for life-critical diagnostic monitoring. Using our nanoDSP and BodyNet™ technology platforms, the Company manufactures microelectronics, micro-mechanical assemblies, high-precision injection-molded plastic components and complete bio-telemetry devices for emerging and leading medical device manufacturers. The medical industry is faced with pressures to reduce the cost of healthcare. Driven by core technologies, such as the IntriCon Physiolink™ that wirelessly connects patients and care givers in non-traditional ways, IntriCon helps shift the point of care from expensive traditional settings, such as hospitals, to less expensive non-traditional settings like the home. IntriCon currently serves this market by offering medical manufacturers the capabilities to design, develop, manufacture and distribute medical devices that are easier to use, are more miniature, use less power, and are lighter. Increasingly, the medical industry is looking for wireless, low-power capabilities in their devices.

IntriCon currently has a strong presence in the diabetes and other bio-telemetry markets. For diabetes, IntriCon has partnered with Medtronic to manufacture their wireless continuous glucose monitors (CGM), sensors, and accessories associated with Medtronic’s CGM system, including the MiniMed Connect, which links the MiniMed pump and CGM to certain smart devices providing users with a discrete and real-time view of their blood sugar information. Our Medtronic business posted record revenue in 2015, led by the MiniLink REAL-Time Transmitter and related accessories sales, which are incorporated in Medtronic’s MiniMed 530G insulin pump and CGM system. In August 2016, the FDA approved the MiniMed 630G system which will replace the 530G system. In addition to the MiniMed 630G system, IntriCon is also designed into the MiniMed 670G system which was approved by the FDA in September 2016.The MiniMed 670G is the world’s first hybrid closed loop insulin delivery system and we are excited to be designed into and supporting such a revolutionary diabetes management system. In June 2017, the 670G was launched in the U.S. Medtronic began fulfilling orders from patients enrolled in their Priority Access Program. In parallel, Medtronic began taking new orders from interested customers who want to be next in line to receive the system after the Priority Access orders are filled. Looking ahead, we believe there are opportunities to expand our diabetes product offering with Medtronic, as well as move into new markets outside of the diabetes market.

IntriCon has a suite of medical coils and micro coils that it offers to various original equipment manufacturing (OEM) customers. These products are currently used in pacemaker programming and interventional catheter positioning applications.

IntriCon manufactures bubble sensors and flow restrictors that monitor and control the flow of fluid in an intravenous infusion system as well as a family of safety needle products for an OEM customer that utilizes IntriCon’s insert and straight molding capabilities. These products are assembled using full automation, including built-in quality checks within the production lines.


Lastly, IntriCon is targeting other emerging biotelemetry and home care markets that could benefit fromthrough its already developed core competencies and capabilities to develop devices that are more technologically advanced, smaller and lightweight. To do so, IntriCon

For additional information on the Company’s markets and core technologies refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

Results of Operations

Overall Results

First quarter 2022 results included the following:

GAAP diluted net loss per share was $0.07.

Adjusted non-GAAP diluted net income per share was $0.24.

Total revenue increased 4.1% over the prior year, driven by demand growth of our Diabetes products.

Gross profit as a percent of revenue increased 1.0% due, in part, to increased volume and product mix.

Operating loss for the quarter was ($429) compared to operating income of $848 in the comparable prior period, driven by one-time merger related costs.

Revenue, net

Below is leveraging its resourcesa summary of our revenue by main markets for the three months ended March 31, 2022 and 2021:

          

Change

 

Three Months Ended March 31,

 

2022

  

2021

  

Dollars

  

Percent

 

Diabetes

 $20,323  $18,364  $1,959   10.7%

Interventional Catheters

  3,271   3,802   (531)  -14.0%

Other Medical

  3,699   2,958   741   25.1%

Hearing Health Value Based DTEC

  685   937   (252)  -26.9%

Hearing Health Value Based ITEC

  1,144   1,301   (157)  -12.1%

Hearing Health Legacy OEM

  2,726   3,421   (695)  -20.3%

Professional Audio Communications

  1,212   985   227   23.0%

Total Net Revenue

 $33,060  $31,768  $1,292   4.1%

For the three months ended March 31, 2022, we experienced an increase of 10.7%, in sales and marketing and research and developmentnet revenue in the diabetes medical market compared to the same period in 2021 primarily driven by increased product demand in anticipation of future product launches.

Interventional catheters net revenues for the three months ended March 31, 2022 decreased 14.0% compared to the same period in 2021 due to supply chain constraints.

Other medical net revenue for the three months ended March 31, 2022 increased 25.1% compared to the same period in 2021. The increase was driven by commercialization of newly developed products as the Company continues to expand its reachsurgical navigation product offering.

Net revenue in our hearing health value based DTEC business for the three months ended March 31, 2022 decreased 26.9% compared to other large medical devicethe same period in 2021 due to the reduced investment and restructuring of this business beginning in the second quarter 2020.

Net revenue in our hearing health carevalue based ITEC business for the three months ended March 31, 2022 decreased 12.1% compared to the same period in 2021. The decline was due to supply chain constraints of key components. 

Net revenue in our hearing health legacy OEM business for the three months ended March 31, 2022 decreased 20.3% compared to the same period in 2021 due to timing of orders and supply chain constraints.

Net revenue to the professional audio communications sector for the three months ended March 31, 2022 increased 23.0% compared to the same period in 2021 due to increased product demand and easing of COVID restrictions in Singapore.

Gross Profit

Gross profit, both in dollars and as a percent of revenue, for the three months ended March 31, 2022 and 2021, was as follows:

Three Months Ended March 31,

 

2022

  

2021

  

Change

 
      

Percent

      

Percent

         
  

Dollars

  

of Revenue

  

Dollars

  

of Revenue

  

Dollars

  

Percent

 

Gross Profit

 $8,872   26.8% $8,210   25.8% $662   8.1%

Gross profit as a percentage of revenue for the three months ended March 31, 2022 increased 1.0% from the prior period due, in part, to increased demand and product mix.

Operating Expenses

Operating expenses for the three months ended March 31, 2022 and 2021 were as follows:

Three Months Ended March 31,

 

2022

  

2021

  

Change

 
      

Percent

      

Percent

         
  

Dollars

  

of Revenue

  

Dollars

  

of Revenue

  

Dollars

  

Percent

 

Sales and marketing

 $2,318   7.0% $1,982   6.2% $336   17.0%

General and administrative

  4,310   13.0%  4,052   12.8%  258   6.4%

Research and development

  1,587   4.8%  1,293   4.1%  294   22.7%

Merger-related costs

  1,032   3.1%  -   0.0%  1,032   100.0%

Other operating expenses

  54   0.2%  35   0.1%  19   54.3%

Sales and marketing expenses for the three months ended March 31, 2022, increased compared to the respective prior periods due to an increase in internal sales compensation and incentives tied to headcount and year-over-year sales improvement.

General and administrative expenses for the three months ended March 31, 2022, increased from the prior year period due to higher salaries, wages, incentives, and third-party fees. 

Research and development expenses for the three months ended March 31, 2022 increased compared to the prior year period due to the expansion of developing new products. 

Merger-related costs include legal, consulting and accounting fees associated with the negotiation and execution of the Merger Agreement with entities affiliated with Altaris Capital LLC in the first quarter of 2022. See note 2.

Other operating expenses relates to changes in the fair value of the contingent consideration liability.

Interest expense, net

Interest expense, net for the three months ended March 31, 2022 was $1 compared to $9 for the comparable period in 2021.

Other expense, net

Other expense, net for the three months ended March 31, 2022 was $152 compared to $77 for the same periods in 2021. The increase in expense over the prior year period was due to a reduction in funds received from the Singapore government paid to our subsidiaries for COVID-19 relief and employment credits received in 2021.

Income tax expense

Income tax expense for the three months ended March 31, 2022 was $15 compared to $90 for the same periods in 2021. The change in income tax expense relates to a decrease in estimates for foreign income taxes for the year-to-date period.

Net (Loss) Income

Net (loss) income and non-GAAP adjusted net income are as follows:

  

Three Months Ended

 
  

March 31,

  

March 31,

 
  

2022

  

2021

 

Net (loss) income - GAAP attributable to Intricon

 $(657) $714 

Identified adjustments attributable to Intricon:

        

Depreciation (1)

  874   841 

Amortization of intangibles (2)

  528   497 

Stock-based compensation (3)

  481   453 

Other amortization (4)

  58   102 

Fair value of contingent consideration (5)

  38   35 

COVID-19 Singapore government support (6)

  -   (121)

Merger Related Costs (7)

  1,032   - 

Non-GAAP adjusted net income attributable to Intricon (8)

 $2,354  $2,521 
         

Average basic shares outstanding

  9,256   8,994 

Average diluted shares outstanding

  9,712   9,607 

Non-GAAP adjusted net income attributable to Intricon per diluted share

 $0.24  $0.26 

(1) Depreciation represents the expense of property, plant and equipment.

(2) These expenses represent amortization expenses of intangible assets.

(3) Stock-based compensation represents expenses related to awards under the Company's equity incentive plans.

(4) These expenses represent amortization of other assets.
(5) These expenses represent changes in the fair value of contingent consideration in the period for the purchase of EMS.
(6) The Singapore Government provided COVID-19 financial assistance to our Singapore subsidiaries during the first quarter of 2021.
(7) In February of 2022, the Company entered into a Merger Agreement with affiliates of Altaris Capital Partners LLC. In connection with the negotiation and execution of the Merger Agreement, the Company incurred $1,032 in legal, accounting and consulting fees.

(8) None of these adjustments have material income tax impacts due to the Company's net loss position as of March 31, 2022.

Liquidity and Capital Resources

We continue to maintain adequate liquidity to operate our businesses. As of March 31, 2022, we had $5,311 of cash and cash equivalents on hand as well as $15,457 of short-term investment securities maturing within the next twelve months for a total of $20,768 of liquid capital. Sources of our cash for the three months ended March 31, 2022 have been from our operating and investing activities, as described below. The Company’s cash flows from operating, investing and financing activities, as reflected in the statement of cash flows, are summarized as follows:

  

Three Months Ended

 
  

March 31, 2022

  

March 31, 2021

 

Cash provided by (used in):

        

Operating activities

 $(1,658) $5,865 

Investing activities

  1,627   (2,511)

Financing activities

  (311)  (245)

Effect of exchange rate changes on cash

  62   22 

Net (decrease) increase in cash

 $(280) $3,131 

Net cash used in operating activities was $1,658 for the three months ended March 31, 2022, compared to $5,865 net cash provided by for the same period in 2021 primarily due to increasing inventories to meet forecasted demand as well as inflationary pressures.

Net cash provided by investing activities was $1,627 for the three months ended March 31, 2022, compared to $2,511 used in investing activities, for the same period in 2021. The variance was primarily the result of timing of purchases and maturities of the Company's investments. 

Net cash used in financing activities was $311 for the three months ended March 31, 2022 compared to $245 for the same period in 2021 primarily due to payments on liabilities related to intangible assets.

The Company had the following bank arrangements at March 31, 2022:

Domestic Credit Facilities

The Company and its domestic subsidiaries are parties to a credit facility with CIBC Bank USA. The credit facility, as amended through the date of this filing, provides for a $12,000 revolving credit facility, with a $200 sub facility for letters of credit. Under the revolving credit facility, the availability of funds depends on a borrowing base composed of stated percentages of the Company’s eligible trade receivables and eligible inventory, and eligible equipment less a reserve. The credit facility matures on December 15, 2022.

The Company was in compliance with all applicable covenants under the credit facility as of March 31, 2022.

Foreign Credit Facility

In addition to its domestic credit facilities, the Company’s wholly-owned subsidiary, Intricon, PTE LTD., has an international senior secured credit agreement with Oversea-Chinese Banking Corporation Ltd. that provides for an asset-based line of credit. Borrowings bear interest at a rate of .75% to 2.5% over the lender’s prevailing prime lending rate.

Capital Adequacy

We believe that funds expected to be generated from operations, funds maintained in liquid investments and funds available under our revolving credit loan facility will be sufficient to meet our anticipated cash requirements for operating needs for at least the next 12 months. While management believes that we will be able to meet our liquidity needs for at least the next 12 months, no assurance can be given that we will be able to do so.

As of March 31, 2022, and December 31, 2021, the Company had a total borrowing capacity under its credit facilities of $14,291 and $14,294, respectively, with no borrowings outstanding at the end of each reporting period.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are detailed in “Note 1: Summary of Significant Accounting Policies” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The Company follows these policies in preparation of the condensed consolidated financial statements.

Non-GAAP Financial Measures

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include adjusted net income and adjusted net income per diluted share.

These non-GAAP financial measures reflect adjustments for expenses and gains that the Company believes do not reflect the Company’s core operating performance. The Company has presented these non-GAAP financial measures because the Company believes this presentation, when reconciled to the corresponding GAAP measures, provides useful information to investors in evaluating the Company’s operational performance. Management uses these non-GAAP measures internally to evaluate our performance and in making financial, operational and planning decisions, including with respect to incentive compensation. The Company believes that the presentation of these measures provides investors with greater transparency with respect to the Company's results of operations and that these measures are useful for period-to-period comparison of results and trends. The Company further believes that the use of these non-GAAP financial measures provides an additional tool for investors in comparing the Company’s financial results with the financial results of other companies.

 

In order to focusThe Company periodically reassesses the components of non-GAAP adjustments for changes in how the Company evaluates its performance, changes in how the Company makes financial and operational resources on value based hearing healthcaredecisions, and considers the growing DTC opportunity, IntriCon madeuse of these measures by Intricon's competitors and peers to ensure the strategic decision to divest its non-core CDM business in 2016. The Company sold the cardiac diagnostic monitoring business on February 17, 2017 to Datrix, LLC.adjustments are still relevant and meaningful.

 

Professional Audio CommunicationsNon-GAAP financial measures should not be used as a substitute for GAAP measures, or considered in isolation, for the purpose of analyzing our operating performance. The presentation of these non-GAAP financial measures should not be construed as an inference that future results will not be affected by similar items.

 

IntriCon entered the high-quality audio communication device market in 2001, and now has a line of miniature, professional audio headset products used by customers focusing on emergency response needs. The line includes several communication devices that are extremely portable and perform well in noisy or hazardous environments. These products are well suited for applications in the fire, law enforcement, safety, aviation and military markets. In addition, the Company has a line of miniature ear- and head-worn devices used by performers and support staff in the music and stage performance markets. We believe performance in difficult listening environments and wireless operations will continue to improve as these products increasingly include our proprietary nanoDSP, wireless nanoLink and PhysioLink technologies.

Core Technologies Overview

Our core technologies expertise is focused on three main markets: medical bio-telemetry, value based hearing healthcare and professional audio communications. Over the past several years, the Company has increased investments in the continued development of five critical core technologies: Ultra-Low-Power (ULP) Digital Signal Processing (DSP), Fitting Software, ULP Wireless, Microminiaturization, and Miniature Transducers. These five core technologies serve as the foundation of current and future product platform development, designed to meet the rising demand for smaller, portable, more advanced devices and the need for greater efficiencies in the delivery models. The continued advancements in this area have allowed the Company to further enhance the mobility and effectiveness of miniature body-worn devices.

ULP DSP

DSP converts real-world analog signals into a digital format. Through our nanoDSP™ technology, IntriCon offers an extensive range of ULP DSP amplifiers for hearing, medical and professional audio applications. Our proprietary nanoDSP incorporates advanced ultra-miniature hardware with sophisticated signal processing algorithms to produce devices that are smaller and more effective. The Company further expanded its DSP portfolio including improvements to its Reliant CLEAR™ feedback canceller, offering increased added stable gain and faster reaction time. Additionally, the DSP technologies are utilized in the Audion8™, our eight-channel hearing aid amplifier, and the Audion16™, our wide dynamic range compression sixteen-channel hearing aid amplifier announced in April 2016. The amplifiers are feature-rich and are designed to fit a wide array of applications. In addition to multiple compression channels, the amplifiers have a complete set of proven adaptive features which greatly improve the user experience.

ULP Wireless

Wireless connectivity is fast becoming a required technology, and wireless capabilities are especially critical in new body-worn devices. IntriCon’s BodyNet™ ULP technology, including the nanoLink™ and PhysioLink™ wireless systems, offers solutions for transmitting the body’s activities to caregivers, and wireless audio links for professional communications and surveillance products, including diabetes monitoring and audio streaming for hearing devices.

IntriCon is in the final stages of commercializing its PhysioLink2 and Physiolink3 wireless technology, which will be incorporated into product platforms serving the medical, hearing health and professional audio communication markets. This system is based on 2.4GHz proprietary digital radio protocol in the industrial-scientific-medical (ISM) frequency band and enables audio and data streaming and command and control to ear-worn and body-worn applications over distances of up to five meters. The Physiolink2 technology can be used to increase productivity in the emerging VBHH channels through in office wireless programming, remote cloud based fitting and consumer directed self-fitting of hearing aids. This will provide both greater access and lower costs for patients. In addition, remote control functions will improve the patient experience while using the device especially for those with diminished dexterity. The Physiolink3 technology builds on the Physiolink2 capabilities by adding wireless streaming at much lower power levels than any technology currently on the market. This will allow for accessories to enhance the user experience in noisy environments by allowing audio streaming directly to the hearing aid.


Fitting Software

The ability to efficiently and effectively fit hearing aids is critical to building a value based eco-system of hearing healthcare. By developing more advanced fitting software systems, individuals can benefit from fittings that conform to their specific loss, while eliminating the need for an in-person appointment. In addition to the traditional fitting software, IntriFit, used in the conventional channel, IntriCon has made significant investments in various advanced fitting software solutions that can enable remote and self-fitting solutions. IntriCon believes these advanced fitting solutions, along with the other components of the eco-system, will drive access, affordability and superior customer satisfaction to the millions individuals that cannot receive care today, primarily due to high cost and low access. IntriCon will be introducing our advanced fitting solutions through our various VBHH channels later in 2017.

Microminiaturization

IntriCon excels at miniaturizing body-worn devices. We began honing our microminiaturization skills over 30 years ago, supplying components to the hearing health industry. Our core miniaturization technology allows us to make devices for our markets that are one cubic inch and smaller. We also are specialists in devices that run on very low power, as evidenced by our ULP wireless and DSP. Less power means a smaller battery, which enables us to reduce size even further, and develop devices that fit into the palm of one’s hand.

Miniature Transducers

IntriCon’s advanced transducer technology has been pushing the limits of size and performance for over a decade. Included in our transducer line are our miniature medical coils and micro coils used in pacemaker programming and interventional catheter positioning applications. We believe that with the increase of greater interventional care, our coil technology harbors significant value.

Forward-Looking and Cautionary Statements

 

Certain statements included in this Quarterly Report on Form 10-Q or documents the Company files with the Securities and Exchange Commission, which are not historical facts, or that include forward-looking terminology such as “may”, “will”, “believe”, “anticipate”, “expect”, “should”, “optimistic” “continue”, “estimate”, “intend”, “plan”, “would”, “could”, “guidance”, “potential”, “opportunity”, “project”, “forecast”, “confident”, “projections”, “schedule”“scheduled”, “designed”, “future”, “discussion”, “if” or the negative thereof or other variations thereof, are forward-looking statements (as such term is defined in Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, and the regulations thereunder), which are intended to be covered by the safe harbors created thereby. These statements may include, but are not limited to statements in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Notes to the Company’s Condensed Consolidated Financial Statements” such as risks in connection with the Merger Agreement and the Merger, estimates of future results, the expected results and impacts of the EMS acquisition, statements regarding the effects of the COVID-19 pandemic, statements regarding the estimated costs and expenses of the restructuring and estimated annual expense savings, net operating loss carryforwards, the ability to meet cash requirements for operating needs, the ability to meet liquidity needs, assumptions used to calculate future level of funding of employee benefit plans, the adequacy of insurance coverage and the impact of new accounting pronouncements and litigation. Forward-looking statements also include, without limitation, statements as to the Company’sCompany's expected future results of operations and growth, strategic alliances and their benefits, government regulation, potential increases in demand for the Company’s products, the Company’s ability to meet working capital requirements, the Company’sCompany's business strategy, the expected increases in operating efficiencies, anticipated trends in the Company’sCompany's markets, estimates of goodwill impairments and amortization expense of other intangible assets, the effects of changes in accounting pronouncements, the effects of litigation and the amount of insurance coverage, and statements as to trends or the Company’sCompany's or management’smanagement's beliefs, expectations and opinions.

 

Forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements. In addition to the factors discussed in this Quarterly Report on Form 10-Q, certain risks, uncertainties and other factors can cause actual results and developments to be materially different from those expressed or implied by such forward-looking statements, including without limitation, the following:

our ability to successfully implement our business and growth strategy;

risks arising in connection with the insolvency of our former subsidiary, Selas SAS, and potential liabilities and actions arising in connection with the insolvency;

the volume and timing of orders received by the Company, particularly from Medtronic and hi HealthInnovations;

changes in estimated future cash flows;

our ability to collect our accounts receivable;

foreign currency movements in markets that we serve;

changes in the global economy and financial markets;


weakening demand for our products due to general economic conditions;

changes in the mix of products sold;

our ability to meet demand;

changes in customer requirements;

timing and extent of research and development expenses;

FDA approval, timely release and acceptance of our products and those of our customers;

competitive pricing pressures;

pending and potential future litigation;

cost and availability of electronic components and commodities for our products;

our ability to create and market products in a timely manner and develop products that are inexpensive to manufacture;

our ability to comply with covenants in our debt agreements or to obtain waivers if we do not comply;

our ability to repay debt when it comes due;

our ability to obtain extensions of our current credit facility or a new credit facility;

the loss of one or more of our major customers;

our ability to identify, complete and integrate acquisitions;

effects of legislation;

effects of foreign operations;

our ability to develop new products;

our ability to recruit and retain engineering and technical personnel;

the costs and risks associated with research and development investments;

the recent recessions in Europe and the debt crisis in certain countries in the European Union;

our ability and the ability of our customers to protect intellectual property;

cybersecurity threats;

loss of members of our senior management team; and

other risk factors set forth in our most recent Annual Report on Form 10-K or any prior Quarterly Report on Form 10-Q, which are incorporated by reference into this Report.

For a description of these and other risks, see Part I,those described within “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2016,2021 and the other risks described elsewhere in this Quarterly Report on Form 10-Q, or in other filings the Company makes from time to time with the Securities and Exchange Commission. The Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.

 

Critical Accounting Policies

The preparation

25